Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 505 • 2014 ACR/ARHP Annual Meeting
A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Ani John¹, George Quartey¹, Patricia B. Lehane², Nicole Mairon³, Michael Schulte³, Ashwini Shewade¹, Carol Chung¹ and Dominic Borie¹, ¹Genentech, Inc, South San Francisco, CA, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Rituximab in combination with methotrexate (MTX) is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have…
Abstract Number: 2936 • 2014 ACR/ARHP Annual Meeting
Is Ankylosing Spondylitis a Risk Factor for Cardiovascular Diseases, and How Does These Risks Compare to Those in Rheumatoid Arthritis?
Johan Askling¹, Lennart Jacobsson² and Jonas Eriksson¹, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²sahlrenska academy, gothenburg, Sweden
Background/Purpose Patients with RA are at increased risk of cardiovascular (CV) diseases, including acute coronary syndromes (ACS), deep venous thromboembolism (DVT) and pulmonary embolism (PE),…
Abstract Number: 2024 • 2014 ACR/ARHP Annual Meeting
Prevalence of Rheumatoid Arthritis in French West Indies, an African Ancestry Population. the Eppra Study
Michel De Bandt¹, Rishika Banydeen², Lauren Brunier³, Katleen Polomat⁴, Veronique Dehlinger⁵, Serge Arfi⁴, Christophe Deligny⁴, Benedicte Garnery⁶, Helene Cormier⁷, Fabienne Dubreuil⁸, Patrick Numeric⁹, Danielle Dufrenot¹⁰, Sabine Molcard⁷, Loic Brithmer⁷, Olivier Fuhrer⁷, Lucien Louis-Joseph¹¹, Sylvie Merle² and Georges Jean-Baptiste⁵, ¹CHUM de Martinique, Unit of rheumatology, Fort de France, France, ²Hôpital universitaire P Zobda-Quitman, CHU de Martinique,, Unit of epidemiology and biostatistics, Fort de FRance, France, ³CHUM de Martinique,, Unit of rheumatology, CHUM, 97200 Fort de France, France, ⁴CHUM de Martinique,, unit of internal medicine, Fort de France, France, ⁵CHUM de Martinique,, Unit of rheumatology, CHUM, Fort de France, France, ⁶Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of internal medicine, Fort de France, France, ⁷Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fort de France, France, ⁸Hôpital universitaire P Zobda-Quitman, CHU de Martinique,, Unit of rheumatology, Fort de FRance, France, ⁹route de Chateauboeuf, 97200; French West Indies, Unit of rheumatology, CHUM, Fort de France, France, ¹⁰Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fot de France, France, ¹¹Hôpital universitaire P Zobda-Quitman, CHU de Martinique, Unit of rheumatology, Fort de FRance, France
Background/Purpose Rheumatoid arthritis (RA) is a disabling chronic disease, regarded as the most frequent inflammatory rheumatism in adults, with a prevalence estimated between 0.3 and…
Abstract Number: 1385 • 2014 ACR/ARHP Annual Meeting
What Discriminates Best Flares in Rheumatoid Arthritis (RA)? a Subanalysis of the Strass Treatment Tapering in RA Study
Agnès Danré¹, Bruno Fautrel², Toni Alfaiate³, Thao Pham⁴, Jacques Morel⁵, Emmanuelle Dernis Labous⁶, Philippe Gaudin⁷, Olivier Brocq⁸, Elisabeth Solau-Gervais⁹, Jean-Marie Berthelot¹⁰, Jean Charles Balblanc¹¹, Xavier Mariette¹², Florence Tubach¹³ and Laure Gossec¹⁴, ¹Rheumatology, La Pitié Salpêtrière, Paris, France, ²Rheumatology, Pitie Salpetriere Hospital, Paris, France, ³department of epidemiology, biostatistics and clinical research, APHP, Hospital Bichat, Paris, France, ⁴Rheumatology, Sainte Marguerite Hospital, Marseille, France, ⁵Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ⁶Rhumatologie, Ch Du Mans, Le Mans, France, ⁷Rhumatologie, Hopital Sud Grenoble, Echirolles, France, ⁸Rheumatology, Hospital of Princesse Grâce de Monaco, Monaco, France, ⁹Rheumatology, University Hospital of Poitiers, Poitiers, France, ¹⁰Rheumatology, CHU Nantes (Nantes University Hospital), Nantes, France, ¹¹Rhumatologie, Ch de Belfort, Belfort Cedex, France, ¹²Rheumatology, University Hospital, Le Kremlin Bicetre, Paris, France, ¹³INSERM, Universite Paris Diderot, Paris, France, ¹⁴Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose Flares in rheumatoid arthritis (RA) are a patient-perceived increase of disease activity which might be particularly important to assess in the context of treatment…
Abstract Number: 459 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis
J. Kremer¹, A.J. Kivitz², J.a. Simon Campos³, E.L. Nasonov⁴, H. Tony⁵, B. Vlahos⁶, C. Hammond⁶, J. Bukowski⁶, H. Li⁶, S. Schulman⁶, S. Raber⁷, A. Zuckerman⁸ and J. Isaacs⁹, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Altoona Center for Clinical Research, Duncansville, PA, ³Hospital CEM/BIOCEM, Merida, Mexico, ⁴Nasonova State Institute of Rheumatology, Moscow, Russia, ⁵University Hospital Würzburg, Würzburg, Germany, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, San Diego, CA, ⁸Pfizer Inc, Groton, CT, ⁹National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom
Background/Purpose: In the clinical development program of the oral Janus kinase inhibitor tofacitinib for the treatment of rheumatoid arthritis (RA), small mean increases in serum…
Abstract Number: 2927 • 2014 ACR/ARHP Annual Meeting
Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Priyanka Vashisht¹, Jessica M. Dorschner², Mark A. Jensen³, Beverly Chrabot⁴, Theresa Wampler Muskardin⁵, Marlena Kern⁶, Tetrad Investigators⁷, ABCoN Consortium⁸, S. Louis Bridges Jr.^9,10, P.K. Gregersen¹¹ and Timothy B. Niewold², ¹Division of Rheumatology and Department of Immunology, University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁴Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁶North Shore Univ Hospital, Feinstein Institute for Medical Research, Manhasset, NY, ⁷AL, ⁸NY, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹¹The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA). Previous studies have suggested that circulating type I interferon (IFN)…
Abstract Number: 1962 • 2014 ACR/ARHP Annual Meeting
Inflammatory Properties of Inhibitor of DNA Binding 1 As a Unique Fibroblast Derived Nuclear Protein
Gautam Edhayan¹, Christine M. Ha¹, Ray A. Ohara¹, Takeo Isozaki¹, M. Asif Amin¹, Ali Arbab², Pei-Suen Tsou³, Phillip L. Campbell⁴, Elena Schiopu³, Dinesh Khanna³, Rachel Morgan¹, Sean C. Friday¹, David A. Fox¹ and Jeffrey Ruth¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Georgia Regents University, Augusta, GA, ³University of Michigan Scleroderma Program, Ann Arbor, MI, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Inhibitor of DNA binding 1 (Id1) is a nuclear protein containing a basic helix-loop-helix (bHLH) domain that regulates cell growth by selective binding and…
Abstract Number: 1368 • 2014 ACR/ARHP Annual Meeting
Are Tender Joints Better Than Synovitis to Predict Structural Damage in Rheumatoid Arthritis?
Peter Cheung¹, Karine Mari², Valerie Devauchelle³, Jacques Bentin⁴, Sandrine Jousse-Joulin⁵, Maria-Antonietta d'Agostino⁶, Gérard Chales⁷, Isabelle Chary-Valckenaere⁸, Fabien Etchepare⁹, Philippe Gaudin¹⁰, Xavier Mariette¹¹, Alain Saraux¹² and Maxime Dougados¹³, ¹Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²RCT, Lyon, France, ³Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ⁴Rheumatology, CHU-Brugmann, Brussels, Belgium, ⁵Rheumatology, CHU Brest, Brest, France, ⁶Rheumatology, Versailles-Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁷Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ⁸Rheumatology, Nancy University Hospital, Nancy, France, ⁹AP-HP, La Pitié-Salpétrière Hospital, Rheumatology Department, Paris-VI University, Paris, France, ¹⁰Rhumatologie, Hopital Sud Grenoble, Echirolles, France, ¹¹Paris-Sud University, Paris, France, ¹²Rhumatologie, CHU Brest and EA 2216, UBO, Brest, France, ¹³Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: Longitudinal studies indicate that synovitis can predict subsequent structural damage in rheumatoid arthritis (RA) but the clinical relevance of tenderness is unclear. The aim…
Abstract Number: 469 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study
Andrea Cuervo¹, M. Victoria Hernández¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B…
Abstract Number: 2383 • 2013 ACR/ARHP Annual Meeting
A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis
Chiara Stagnaro¹, Claudia Ferrari², Rosaria Talarico³, Camillo Giacomelli¹, Stefano Bombardieri¹ and Laura Bazzichi¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Pisa, Italy
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
Abstract Number: 1888 • 2013 ACR/ARHP Annual Meeting
Transcriptional Regulation Of Peptidylarginine Deiminase Type IV: Implications For Rheumatoid Arthritis
Ali Abbas¹, Kevin Le¹, Virginia Pimmett¹, David A. Bell², Ewa Cairns² and Rodney P. DeKoter¹, ¹Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: High titers of anti-citrullinated protein/peptide antibodies (ACPA) have been detected in sera of rheumatoid arthritis (RA) patients, implicating citrullinating enzymes in the pathogenesis of…
Abstract Number: 877 • 2013 ACR/ARHP Annual Meeting
Results From The RATE-RA Study: A Multicenter, Single-Arm Study To Evaluate The Safety Of Administering Rituximab At a More Rapid Infusion Rate In Patients With Rheumatoid Arthritis
Charles H. Pritchard¹, Maria W. Greenwald², Joel M. Kremer³, Norman B. Gaylis⁴, William Rigby⁵, Steve Zlotnick⁶, Carol Chung⁷, Birgit Jaber⁸ and William Reiss⁹, ¹Rheumatology, Drexel University College of Medicine, Willow Grove, PA, ²Desert Medical Advances, Palm Desert, CA, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁵Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁶Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ⁷Genentech Inc., South San Francisco, CA, ⁸F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁹Genentech, South San Francisco, CA
Background/Purpose: The FDA-approved dose of rituximab (RTX) in rheumatoid arthritis (RA) is 2 × 1000 mg IV infusions given 2 weeks apart (1 course), with…
Abstract Number: 2335 • 2013 ACR/ARHP Annual Meeting
Epstein-Barr Virus In Peripheral Blood Of Rheumatoid Arthritis Patients Predicts Response To Rituximab Therapy
Heikki Valleala¹, Markku Korpela², Markku J. Kauppi³ and Yrjo T. Konttinen⁴, ¹Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ²Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ³Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁴Dept of Medicine, Helsinki Univ Central Hospital, Helsinki, Finland
Background/Purpose: Autoreactive B-cells infected by Epstein-Barr virus (EBV) are suspected to be involved in the aetiology of various human chronic autoimmune diseases. The aim of…
Abstract Number: 1833 • 2013 ACR/ARHP Annual Meeting
Combination Of TNF and IL-6 Induces Osteoclast-Like Cells With Bone-Resorption Activity Both In Vitro and In Vivo
Kazuhiro Yokota, Kojiro Sato and Toshihide Mimura, Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Although TNF inhibitors suppress bone destruction in patients with rheumatoid arthritis (RA), TNFα stimulation alone does not directly induce osteoclasts, bone-resorbing cells. With the…
Abstract Number: 772 • 2013 ACR/ARHP Annual Meeting
Neovascularization and CD15s Influence Long Distance Migration Of Synovial Fibroblasts From Patients With Rheumatoid Arthritis
Birgit Zimmermann¹, Sina Köppert¹, Stephanie Lefèvre¹, Stefan Rehart², Ulf Müller-Ladner¹ and Elena Neumann³, ¹Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, ³Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany
Background/Purpose: Rheumatoid arthritis (RA) synovial fibroblasts (SF) are central cells of cartilage destruction and neoangiogenesis. RASF show an increased migratory potential in the synovium towards…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.